Adaptive Biotechnologies Ownership

ADPT Stock

USD 10.66 0.21 1.93%

Adaptive Biotechnologies holds a total of 151.92 Million outstanding shares. The majority of Adaptive Biotechnologies Corp outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Adaptive Biotechnologies to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Adaptive Biotechnologies. Please pay attention to any change in the institutional holdings of Adaptive Biotechnologies Corp as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.

Shares in Circulation

First Issued

2018-03-31

Previous Quarter

147.1 M

Current Value

149.2 M

Avarage Shares Outstanding

134 M

Quarterly Volatility

14.1 M

Covid

Dividend Paid And Capex Coverage Ratio is likely to gain to -24.69 in 2025. Common Stock Shares Outstanding is likely to drop to about 143.1 M in 2025. Net Loss is likely to drop to about (189.2 M) in 2025.

Market Cap Enterprise Value

Build AI portfolio with Adaptive Stock

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Adaptive Biotechnologies Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.

Adaptive Stock Ownership Analysis

About 96.0% of the company shares are held by institutions such as insurance companies. The company recorded a loss per share of 0.95. Adaptive Biotechnologies had not issued any dividends in recent years. Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington. Adaptive Biotechnologies operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 858 people. For more info on Adaptive Biotechnologies Corp please contact Chad MBA at 206 659 0067 or go to https://www.adaptivebiotech.com.

Besides selling stocks to institutional investors, Adaptive Biotechnologies also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Adaptive Biotechnologies' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Adaptive Biotechnologies' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.

Adaptive Biotechnologies Quarterly Liabilities And Stockholders Equity

510.85 Million

Adaptive Biotechnologies Insider Trades History

Roughly 2.0% of Adaptive Biotechnologies Corp are currently held by insiders. Unlike Adaptive Biotechnologies' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Adaptive Biotechnologies' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Adaptive Biotechnologies' insider trades

Dot-com Bubble

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Adaptive Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Adaptive Biotechnologies is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Adaptive Biotechnologies Corp backward and forwards among themselves. Adaptive Biotechnologies' institutional investor refers to the entity that pools money to purchase Adaptive Biotechnologies' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.

		Shares
Aristotle Atlantic Partners, Llc	2025-03-31	2.9 M
Geode Capital Management, Llc	2025-03-31	2.8 M
State Street Corp	2025-03-31	2.7 M
Massachusetts Financial Services Company	2025-03-31	2.3 M
Driehaus Capital Management Llc	2025-03-31	2.2 M
Blue Water Life Science Advisors, Llc	2025-03-31	2.1 M
Iron Triangle Partners Lp	2025-03-31	2.1 M
Goldman Sachs Group Inc	2025-03-31	2 M
Victory Capital Management Inc.	2025-03-31	1.8 M
Viking Global Investors Lp	2025-03-31	30 M
Rubric Capital Management Lp	2025-03-31	13.1 M

Note, although Adaptive Biotechnologies' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Adaptive Biotechnologies Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Adaptive Biotechnologies insiders, such as employees or executives, is commonly permitted as long as it does not rely on Adaptive Biotechnologies' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Adaptive Biotechnologies insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

		Kyle Piskel over a month ago Disposition of 248 shares by Kyle Piskel of Adaptive Biotechnologies at 4.98 subject to Rule 16b-3
		Kyle Piskel over two months ago Disposition of 1929 shares by Kyle Piskel of Adaptive Biotechnologies at 8.89 subject to Rule 16b-3
		Griffin Michelle Renee over three months ago Disposition of 36291 shares by Griffin Michelle Renee of Adaptive Biotechnologies at 7.19 subject to Rule 16b-3
		Kyle Piskel over three months ago Disposition of 2500 shares by Kyle Piskel of Adaptive Biotechnologies at 6.32 subject to Rule 16b-3
		Griffin Michelle Renee over three months ago Disposition of 36291 shares by Griffin Michelle Renee of Adaptive Biotechnologies at 7.19 subject to Rule 16b-3
		Hershberg Robert over three months ago Disposition of 53000 shares by Hershberg Robert of Adaptive Biotechnologies at 7.59 subject to Rule 16b-3
		Neupert Peter M over three months ago Disposition of 50000 shares by Neupert Peter M of Adaptive Biotechnologies at 4.07 subject to Rule 16b-3
		Griffin Michelle Renee over three months ago Disposition of 15664 shares by Griffin Michelle Renee of Adaptive Biotechnologies at 7.94 subject to Rule 16b-3
		Griffin Michelle Renee over three months ago Acquisition by Griffin Michelle Renee of 23726 shares of Adaptive Biotechnologies at 8.12 subject to Rule 16b-3
		Francis Lo over three months ago Disposition of 13790 shares by Francis Lo of Adaptive Biotechnologies at 6.99 subject to Rule 16b-3
		Robins Chad M over three months ago Disposition of 211160 shares by Robins Chad M of Adaptive Biotechnologies at 6.32 subject to Rule 16b-3
		Kyle Piskel over six months ago Disposition of 248 shares by Kyle Piskel of Adaptive Biotechnologies at 4.98 subject to Rule 16b-3

Adaptive Biotechnologies Outstanding Bonds

Adaptive Biotechnologies issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Adaptive Biotechnologies uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Adaptive bonds can be classified according to their maturity, which is the date when Adaptive Biotechnologies Corp has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.

	ADANEM 3949 12 FEB 30 Corp Bond US00654GAA13	View
	ADSEZ 42 04 AUG 27 Corp Bond US00652MAG78	View
	MPLX LP 4125 Corp Bond US55336VAK61	View
	MPLX LP 52 Corp Bond US55336VAL45	View
	BNP Paribas FRN Corp Bond USF1R15XK367	View
	Morgan Stanley 3591 Corp Bond US61744YAK47	View
	Valero Energy Partners Corp Bond US91914JAA07	View
	ADAPTHEALTH LLC 6125 Corp Bond US00653VAA98	View

View All Adaptive Biotechnologies Corporate Bonds

Adaptive Biotechnologies Corporate Filings

	9th of July 2025 Other Reports	View Verify
8K	12th of June 2025 Report filed with the SEC to announce major events that shareholders should know about	View Verify
	20th of May 2025 Other Reports	View Verify
F4	19th of May 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities	View Verify

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Adaptive Stock Analysis

When running Adaptive Biotechnologies' price analysis, check to measure Adaptive Biotechnologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Adaptive Biotechnologies is operating at the current time. Most of Adaptive Biotechnologies' value examination focuses on studying past and present price action to predict the probability of Adaptive Biotechnologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Adaptive Biotechnologies' price. Additionally, you may evaluate how the addition of Adaptive Biotechnologies to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2025 Macroaxis LLC